EA-1 mutations in hKv1.1 profoundly alter the gating properties of heteromeric hKv1.1/hKv1.2 channels, providing a physiopathogenetic mechanism for episodic ataxia type-1.
No takes yet. Share an insight, caveat, or question.
May inform EA-1 therapy development targeting channel kinetics; leaves open clinical translation pending human studies.
D’Adamo et al. (1999) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: